Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus

Virus Research

Volumn 213, Issue , 2016, Pages 224-229

  Luczkowiak, Joanna ^a   Arribas, José R ^b   Gómez, Sara ^a   Jiménez Yuste, Víctor ^b   de la Calle, Fernando ^b   Viejo, Aurora ^b   Delgado, Rafael ^a  

^a CAA ^*  (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Convalescent patients; Ebola Virus Disease; Makona Ebola virus; Mayinga Ebola virus; Neutralization assay

Indexed keywords

EBOLA VACCINE; EPITOPE; FAVIPIRAVIR; MONOCLONAL ANTIBODY KZ52; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CONVALESCENCE; DRUG MEGADOSE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; MAKONA EBOLA VIRUS; MAYINGA EBOLA VIRUS; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; VACCINATION; VIRUS NEUTRALIZATION; AFRICA; BLOOD; CENTRAL AFRICA; IMMUNOLOGY; SERODIAGNOSIS;

AFRICA, CENTRAL; AFRICA, WESTERN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS;

EID: 84958749495     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2015.12.019     Document Type: Article

References (37)

1. Alberini I., Del Tordello E., Fasolo A., Temperton N.J., Galli G., Gentile C., Montomoli E., Hilbert A.K., Banzhoff A., Del Giudice G., Donnelly J.J., Rappuoli R., Capecchi B. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009, 27:5998-6003.
2. Alvarez C.P., Lasala F., Carrillo J., Muniz O., Corbi A.L., Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 2002, 76:6841-6844.
3. Baize S., Pannetier D., Oestereich L., Rieger T., Koivogui L., Magassouba N., Soropogui B., Sow M.S., Keita S., De Clerck H., Tiffany A., Dominguez G., Loua M., Traore A., Kolie M., Malano E.R., Heleze E., Bocquin A., Mely S., Raoul H., Caro V., Cadar D., Gabriel M., Pahlmann M., Tappe D., Schmidt-Chanasit J., Impouma B., Diallo A.K., Formenty P., Van Herp M., Gunther S. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 2014, 371:1418-1425.
4. Bale S., Liu T., Li S., Wang Y., Abelson D., Fusco M., Woods V.L., Saphire E.O. Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl. Trop. Dis. 2011, 5:e1395.
5. Barrientos L.G., Lasala F., Otero J.R., Sanchez A., Delgado R. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J. Infect. Dis. 2004, 189:1440-1443.
6. Brecher M., Schornberg K.L., Delos S.E., Fusco M.L., Saphire E.O., White J.M. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J. Virol. 2012, 86:364-372.
7. Brekke O.H., Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2003, 2:52-62.
8. Brudner M., Karpel M., Lear C., Chen L., Yantosca L.M., Scully C., Sarraju A., Sokolovska A., Zariffard M.R., Eisen D.P., Mungall B.A., Kotton D.N., Omari A., Huang I.C., Farzan M., Takahashi K., Stuart L., Stahl G.L., Ezekowitz A.B., Spear G.T., Olinger G.G., Schmidt E.V., Michelow I.C. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 2013, 8:e60838.
9. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of Human-Immuno-Deficiency-Virus Type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
10. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., Buckler-White A., Igarashi T., Theodore T., Byrum R., Kemp C., Montefiori D.C., Martin M.A. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 2001, 75:2224-2234.
11. Gire S.K., Goba A., Andersen K.G., Sealfon R.S., Park D.J., Kanneh L., Jalloh S., Momoh M., Fullah M., Dudas G., Wohl S., Moses L.M., Yozwiak N.L., Winnicki S., Matranga C.B., Malboeuf C.M., Qu J., Gladden A.D., Schaffner S.F., Yang X., Jiang P.P., Nekoui M., Colubri A., Coomber M.R., Fonnie M., Moigboi A., Gbakie M., Kamara F.K., Tucker V., Konuwa E., Saffa S., Sellu J., Jalloh A.A., Kovoma A., Koninga J., Mustapha I., Kargbo K., Foday M., Yillah M., Kanneh F., Robert W., Massally J.L., Chapman S.B., Bochicchio J., Murphy C., Nusbaum C., Young S., Birren B.W., Grant D.S., Scheiffelin J.S., Lander E.S., Happi C., Gevao S.M., Gnirke A., Rambaut A., Garry R.F., Khan S.H., Sabeti P.C. Genomic surveillance elucidates Ebola virus origin and transmission during theoutbreak. Science 2014, 345:1369-1372.
12. Henao-Restrepo A.M., Longini I.M., Egger M., Dean N.E., Edmunds W.J., Camacho A., Carroll M.W., Doumbia M., Draguez B., Duraffour S., Enwere G., Grais R., Gunther S., Hossmann S., Konde M.K., Kone S., Kuisma E., Levine M.M., Mandal S., Norheim G., Riveros X., Soumah A., Trelle S., Vicari A.S., Watson C.H., Keita S., Kieny M.P., Rottingen J.A. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015, 386:857-866.
13. Kaku Y., Noguchi A., Marsh G.A., McEachern J.A., Okutani A., Hotta K., Bazartseren B., Fukushi S., Broder C.C., Yamada A., Inoue S., Wang L.F. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J. Virol. Methods 2009, 160:7-13.
14. Kim Y.B., Lee M.K., Han D.P., Cho M.W. Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res. Hum. Retroviruses 2001, 17:1715-1724.
15. Kreil T.R. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg. Infect. Dis. 2015, 21:521-523.
16. Kreuels B., Wichmann D., Emmerich P., Schmidt-Chanasit J., de Heer G., Kluge S., Sow A., Renne T., Gunther S., Lohse A.W., Addo M.M., Schmiedel S. A case of severe Ebola virus infection complicated by gram-negative septicemia. N. Engl. J. Med. 2014, 371:2394-2401.
17. Kuhn J.H., Andersen K.G., Baize S., Bao Y., Bavari S., Berthet N., Blinkova O., Brister J.R., Clawson A.N., Fair J., Gabriel M., Garry R.F., Gire S.K., Goba A., Gonzalez J.P., Gunther S., Happi C.T., Jahrling P.B., Kapetshi J., Kobinger G., Kugelman J.R., Leroy E.M., Maganga G.D., Mbala P.K., Moses L.M., Muyembe-Tamfum J.J., N'Faly M., Nichol S.T., Omilabu S.A., Palacios G., Park D.J., Paweska J.T., Radoshitzky S.R., Rossi C.A., Sabeti P.C., Schieffelin J.S., Schoepp R.J., Sealfon R., Swanepoel R., Towner J.S., Wada J., Wauquier N., Yozwiak N.L., Formenty P. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses 2014, 6:4760-4799.
18. Ledgerwood J.E., DeZure A.D., Stanley D.A., Novik L., Enama M.E., Berkowitz N.M., Hu Z., Joshi G., Ploquin A., Sitar S., Gordon I.J., Plummer S.A., Holman L.A., Hendel C.S., Yamshchikov G., Roman F., Nicosia A., Colloca S., Cortese R., Bailer R.T., Schwartz R.M., Roederer M., Mascola J.R., Koup R.A., Sullivan N.J., Graham B.S. Chimpanzee adenovirus vector ebola vaccine-preliminary report. N. Engl. J. Med. 2014, [Epub ahead of print].
19. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 454:177-182.
20. Maruyama T., Rodriguez L.L., Jahrling P.B., Sanchez A., Khan A.S., Nichol S.T., Peters C.J., Parren P.W., Burton D.R. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J.Virol. 1999, 73:6024-6030.
21. Marzi A., Feldmann H., Geisbert T.W., Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J. Bioterror Biodef. 2011, S1. 2157-2526-S2151-2004.
22. McElroy A.K., Akondy R.S., Davis C.W., Ellebedy A.H., Mehta A.K., Kraft C.S., Lyon G.M., Ribner B.S., Varkey J., Sidney J., Sette A., Campbell S., Stroher U., Damon I., Nichol S.T., Spiropoulou C.F., Ahmed R. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:4719-4724.
23. Mire C.E., Matassov D., Geisbert J.B., Latham T.E., Agans K.N., Xu R., Ota-Setlik A., Egan M.A., Fenton K.A., Clarke D.K., Eldridge J.H., Geisbert T.W. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 2015, 520:688-691.
24. Murin C.D., Fusco M.L., Bornholdt Z.A., Qiu X., Olinger G.G., Zeitlin L., Kobinger G.P., Ward A.B., Saphire E.O. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:17182-17187.
25. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Wei H., Aviles J., Hiatt E., Johnson A., Morton J., Swope K., Bohorov O., Bohorova N., Goodman C., Kim D., Pauly M.H., Velasco J., Pettitt J., Olinger G.G., Whaley K., Xu B., Strong J.E., Zeitlin L., Kobinger G.P. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
26. Ribeiro-Viana R., Sanchez-Navarro M., Luczkowiak J., Koeppe J.R., Delgado R., Rojo J., Davis B.G. Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nat. Commun. 2012, 3:1303.
27. Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., Lau-Kilby A.W., Johnson J.C., Hensley L., Ammendola V., Abbate A., Grazioli F., Foulds K.E., Cheng C., Wang L., Donaldson M.M., Colloca S., Folgori A., Roederer M., Nabel G.J., Mascola J., Nicosia A., Cortese R., Koup R.A., Sullivan N.J. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 2014, 20:1126-1129.
28. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006, 3:e177.
29. Sullivan N.J., Martin J.E., Graham B.S., Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 2009, 7:393-400.
30. Takada A., Feldmann H., Stroeher U., Bray M., Watanabe S., Ito H., McGregor M., Kawaoka Y. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 2003, 77:1069-1074.
31. Temperton N.J., Chan P.K., Simmons G., Zambon M.C., Tedder R.S., Takeuchi Y., Weiss R.A. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 2005, 11:411-416.
32. WHO Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 2014, 371:1481-1495.
33. Wong G., Kobinger G.P., Qiu X. Characterization of host immune responses in Ebola virus infections. Expert. Rev. Clin. Immunol. 2014, 10:781-790.
34. Wright E., Temperton N.J., Marston D.A., McElhinney L.M., Fooks A.R., Weiss R.A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol. 2008, 89:2204-2213.
35. Yang Z., Delgado R., Xu L., Todd R.F., Nabel E.G., Sanchez A., Nabel G.J. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998, 279:1034-1037.
36. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 2000, 6:886-889.
37. Zhu F.C., Hou L.H., Li J.X., Wu S.P., Liu P., Zhang G.R., Hu Y.M., Meng F.Y., Xu J.J., Tang R., Zhang J.L., Wang W.J., Duan L., Chu K., Liang Q., Hu J.L., Luo L., Zhu T., Wang J.Z., Chen W. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015, 385:2272-2279.